Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
AMAG Will Cut Jobs, Pursue Its Options
by Michael McCoy
November 14, 2011
| A version of this story appeared in
Volume 89, Issue 46
AMAG Pharmaceuticals will cut its workforce of about 225 employees by approximately 25% in an effort to reduce costs. CEO Brian J. G. Pereira is departing, and the company will consider all strategic options to enhance shareholder value and increase sales of its main product, the anemia treatment Feraheme. The moves follow the end of an attempt by AMAG to merge with Allos Therapeutics. Shareholders voted down the move at an Oct. 21 meeting.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter